Freeform Search

Mest 2

Database:

Term:

Display:

Documents in Display Format: Starting with

Number

Generate:

Hit List Hit Count Side by Side Image

Search History

DATE: Tuesday, August 12, 2003 Printable Copy Create Case

Set Name side by side Query

Hit Count

Set Name result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ L9

(14 or 16) same (avidin or streptavidin)

9

L9

L8

(me near dtpa) or (citc near dtpa) or (cyclohexyl near dtpa)

24

L8

L7

4529587.pn.

L6		L7
LU	nor biotin or homo biotin 7	L6
L5	L4 not 12	LO
L4	. 1	L5
	norbiotin or homobiotin 12	L4
L3	L2 not l1	
L2		L3
	biotin same (norbiotin or homobiotin 11	1) L2
L1	biotin near (norbiotin or homobiotin))
	•	L1

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta16191xw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS
      1
NEWS
      2
                 "Ask CAS" for self-help around the clock
                 PCTGEN now available on STN
NEWS
      3
        Feb 24
                TEMA now available on STN
NEWS
        Feb 24
                NTIS now allows simultaneous left and right truncation
NEWS
        Feb 26
NEWS
        Feb 26
                 PCTFULL now contains images
     6
NEWS
     7
        Mar 04
                 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS
     8
        Mar 24
                 PATDPAFULL now available on STN
NEWS
     9
        Mar 24
                 Additional information for trade-named substances without
                 structures available in REGISTRY
                Display formats in DGENE enhanced
        Apr 11
NEWS 10
NEWS 11
                MEDLINE Reload
        Apr 14
NEWS 12
                 Polymer searching in REGISTRY enhanced
        Apr 17
NEWS 13
        Jun 13
                 Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 14
        Apr 21
                 New current-awareness alert (SDI) frequency in
                 WPIDS/WPINDEX/WPIX
        Apr 28
                 RDISCLOSURE now available on STN
NEWS 15
NEWS 16
        May 05
                 Pharmacokinetic information and systematic chemical names
                 added to PHAR
NEWS 17
                 MEDLINE file segment of TOXCENTER reloaded
        May 15
                 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 18
        May 15
NEWS 19
                 Simultaneous left and right truncation added to WSCA
        May 19
NEWS 20
                 RAPRA enhanced with new search field, simultaneous left and
        May 19
                 right truncation
NEWS 21
        Jun 06 Simultaneous left and right truncation added to CBNB
NEWS 22
                PASCAL enhanced with additional data
        Jun 06
NEWS 23
        Jun 20
                2003 edition of the FSTA Thesaurus is now available
NEWS 24
        Jun 25
                HSDB has been reloaded
NEWS 25
        Jul 16 Data from 1960-1976 added to RDISCLOSURE
NEWS 26
        Jul 21
                Identification of STN records implemented
NEWS 27
        Jul 21
                 Polymer class term count added to REGISTRY
NEWS 28
        Jul 22
                 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and
                 Right Truncation available
NEWS 29
        AUG 05
                New pricing for EUROPATFULL and PCTFULL effective
                 August 1, 2003
             April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
NEWS EXPRESS
              MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
              AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS INTER
              General Internet Information
NEWS LOGIN
              Welcome Banner and News Items
NEWS PHONE
              Direct Dial and Telecommunication Network Access to STN
              CAS World Wide Web Site (general information)
NEWS WWW
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus

FILE 'HOME' ENTERED AT 12:26:00 ON 12 AUG 2003

=> fil reg

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

0.21 0.21 FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 12:26:14 ON 12 AUG 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

11 AUG 2003 HIGHEST RN 565156-77-6 STRUCTURE FILE UPDATES: DICTIONARY FILE UPDATES: 11 AUG 2003 HIGHEST RN 565156-77-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

```
=> e norbiotin/cn ·
```

EI	Τ.	NORBINALTRORPHIMINE/CN
E2	1	NORBIOGEST/CN
E3	1>	NORBIOTIN/CN

NORBIOTIN HYDRAZIDE/CN E4 1 NORBIOTIN METHYL ESTER/CN E5 1

E6

E7

E8 ..

1 NORBIOTIN SULFONE/CN
1 NORBIOTIN SULFONE METHYL ESTER/CN
1 NORBIOTIN SULFOXIDE/CN
1 NORBIOTIN, 3A,4,6,6A-TETRADEHYDRO NORBIOTIN, 3A, 4, 6, 6A-TETRADEHYDRO-/CN E9

1 NORBIOTINAMINE/CN E10

1 NORBIPHEN/CN E11

1 NORBISABOLIDE/CN E12

=> s e3

L11 NORBIOTIN/CN

=> d

ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN 1.1

RN669-72-7 REGISTRY

1H-Thieno[3,4-d]imidazole-4-butanoic acid, hexahydro-2-oxo-, (3aS,4S,6aR)-(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

1H-Thieno[3,4-d]imidazole-4-butanoic acid, hexahydro-2-oxo-, [3aS-(3a.alpha., 4.beta., 6a.alpha.)]-

1H-Thieno[3,4-d]imidazole-4-butyric acid, hexahydro-2-oxo- (8CI) OTHER NAMES: CN Norbiotin STEREOSEARCH FS MF C9 H14 N2 O3 S BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, DDFU, DRUGU, LC STN Files: TOXCENTER, USPATFULL (*File contains numerically searchable property data) Absolute stereochemistry. HO₂C_\ (CH₂)₃ S R Η **PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT** 14 REFERENCES IN FILE CA (1947 TO DATE) 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA 14 REFERENCES IN FILE CAPLUS (1947 TO DATE) 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967) => e homobiotin/cn 1 HOMOBENZVALENE/CN E11 HOMOBENZYLPENICILLIN/CN E2 E3 1 --> HOMOBIOTIN/CN HOMOBIOTIN HYDRAZIDE/CN **E4** 1 HOMOBIOTIN METHYL ESTER/CN E5 1 E6 1 HOMOBIOTIN SULFONE/CN **E7** HOMOBIOTIN SULFONE METHYL ESTER/CN 1 HOMOBIOTIN SULFOXIDE/CN E8 1 E9 1 HOMOBORNANE/CN HOMOBORNEOL/CN E10 1 HOMOBOTCINOLIDE/CN E11 1 HOMOBOX-CONTAINING PROTEIN PKNOX 11.11 (HUMAN FETAL BRAIN CL 1 E12 ONE PBS-1729F10)/CN => s e3 1 HOMOBIOTIN/CN L2=> dANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN 1.2 RN 1784-22-1 REGISTRY 1H-Thieno[3,4-d]imidazole-4-hexanoic acid, hexahydro-2-oxo-, (3aS,4S,6aR)-(CA INDEX NAME) (9CI) OTHER CA INDEX NAMES:

1H-Thieno[3,4-d]imidazole-4-hexanoic acid, hexahydro-2-oxo-, stereoisomer

1H-Thieno[3,4-d]imidazole-4-hexanoic acid, hexahydro-2-oxo-,

[3aS-(3a.alpha.,4.beta.,6a.alpha.)]-

CN

CN

CN

CN

FS

OTHER NAMES:

(+)-Homobiotin

Homobiotin

STEREOSEARCH

MF C11 H18 ·N2 O3 S

STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, DDFU, DRUGU, LC TOXCENTER, USPATFULL

(*File contains numerically searchable property data)

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

17 REFERENCES IN FILE CA (1947 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

17 REFERENCES IN FILE CAPLUS (1947 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> fil caplus uspatfull biosis embase medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

12.20. 12.41

FILE 'CAPLUS' ENTERED AT 12:26:46 ON 12 AUG 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:26:46 ON 12 AUG 2003 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:26:46 ON 12 AUG 2003 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 12:26:46 ON 12 AUG 2003 COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 12:26:46 ON 12 AUG 2003

=> d his

(FILE 'HOME' ENTERED AT 12:26:00 ON 12 AUG 2003)

FILE 'REGISTRY' ENTERED AT 12:26:14 ON 12 AUG 2003

E NORBIOTIN/CN

1 S E3 L1

E HOMOBIOTIN/CN

1 S E3 L2

> FILE 'CAPLUS, USPATFULL, BIOSIS, EMBASE, MEDLINE' ENTERED AT 12:26:46 ON 12 AUG 2003

=> s biotin (s) (l1 or l2)

11 BIOTIN (S) (L1 OR L2) L3

=> dup rem 13
PROCESSING COMPLETED FOR L3

L4 11 DUP REM L3 (0 DUPLICATES REMOVED)

=> d ibib abs

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:658989 CAPLUS

DOCUMENT NUMBER: 138:35650

TITLE: Ligand exchange between proteins: exchange of biotin

and biotin derivatives between avidin and streptavidin Pazy, Yael; Kulik, Tikva; Bayer, Edward A.; Wilchek,

AUTHOR(S): Pazy, Yael; Kulik, Tikva; Bayer, Edward A.; W Meir; Livnah, Oded

meir; bivhan, oded

CORPORATE SOURCE: Department of Biological Chemistry, The Institute of

Life Sciences, The Wolfson Centre for Applied Structural Biology, The Hebrew University of

Jerusalem, Jerusalem, 91904, Israel

SOURCE: Journal of Biological Chemistry (2002), 277(34),

30892-30900

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular

Biology

DOCUMENT TYPE: Journal LANGUAGE: English

We have studied the structural elements that affect ligand exchange between the two high affinity biotin-binding proteins, egg white avidin and its bacterial analog, streptavidin. For this purpose, we have developed a simple assay based on the antipodal behavior of the two proteins toward hydrolysis of biotinyl p-nitrophenyl ester (BNP). The assay provided the exptl. basis for these studies. It was found that biotin migrates unidirectionally from streptavidin to avidin. Conversely, the biotin deriv., BNP, is transferred in the opposite direction, from avidin to streptavidin. A previous crystallog. study provided insight into a plausible explanation for these results. These data revealed that the non-hydrolyzable BNP analog, biotinyl p-nitroanilide, was almost completely sheltered in streptavidin as opposed to avidin in which the disordered conformation of a crit. loop resulted in the loss of several hydrogen bonds and concomitant exposure of the analog to the solvent. order to det. the minimal modification of the biotin mol. required to cause the disordered loop conformation, the structures of avidin and streptavidin were detd. with norbiotin, homobiotin, and a common long-chain biotin deriv., biotinyl .epsilon.-aminocaproic acid. Six new crystal structures of the avidin and streptavidin complexes with the latter biotin analogs and derivs. were thus elucidated. It was found that extending the biotin side chain by a single CH2 group (i.e. homobiotin) is sufficient to result in this remarkable conformational change in the loop of avidin. These results bear significant biotechnol. importance, suggesting that complexes contg. biotinylated probes with streptavidin would be more stable than those with avidin. These findings should be heeded when developing new drugs based on lead compds. because it is difficult to predict the structural and conformational consequences on the resultant protein-ligand interactions.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 2 ibib abs

L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:923565 CAPLUS

DOCUMENT NUMBER: 136:42919

TITLE: Biotin derivatives for an extracorporeal device INVENTOR(S): Sandberg, Bengt; Wilbur, Scott; Nilsson, Rune PATENT ASSIGNEE(S): Mitra Medical Technology AB, Swed.; University of

Washington

SOURCE:

PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
APPLICATION NO. DATE
                                 KIND
                                           DATE
       PATENT NO.
                                 · _ _ _ _
                                           ----- .
                                                                   -----
       WO 2001095857
                                   A2
                                           20011220
                                                                   WO 2001-SE1374
                                                                                              20010618
       WO 2001095857
                                   A3
                                           20020328
             W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, BU, TJ
                    KZ, MD, RU, TJ
             RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                                               US 2001-881213
       US 2002159994
                                 A1
                                           20021031
                                                                                              20010615
                              . A5
                                                                   AU 2001-74761
       AU 2001074761
                                           20011224
                                                                                              20010618
                                                                  EP 2001-941404
       EP 1289563
                                  A2
                                           20030312
                                                                                              20010618
              R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                    IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                           20030527
                                                                   BR 2001-11726
                                                                                              20010618
       BR 2001011726
                                 Α
       NO 2002005931
                                           20030214
                                                                   NO 2002-5931
                                                                                              20021211
                                   Α
                                                               SE 2000-2287
PRIORITY APPLN. INFO.:
                                                                                         A 20000616
                                                               US 2000-216625P P
                                                                                              20000707
                                                               WO 2001-SE1374
                                                                                         W 20010618
```

AB A method for the conditioning of an extracorporeal device is described, as well as a method for extracorporeal extn. of toxic material from mammalian body fluids in connection with diagnosis or treatment of a mammalian condition or disease. The methods comprise (i) a soln. contg. a reagent comprising biotin moieties, such as natural biotin or its derivs., and a toxin-binding moiety, (ii) linkers and a trifunctional crosslinking moiety, and (ii) an extracorporeal device comprising said reagent. For example, a dibiotin compd., 1-isothiocyanato-3,5-bis-(13'-biotinamidyl-4',7',10'-trioxatridecanamidyl)-aminoisophthalate was prepd. and conjugated with a toxin-binding mol., i.e., monoclonal antibody 53-6A2. A dibiotin-toxin-binding conjugate was used for conditioning of an avidin-agarose column suitable for removal of toxins from blood.

=> d 3 ibib abs

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2000:433866 CAPLUS

DOCUMENT NUMBER:

133:248664

TITLE:

Biotin Reagents for Antibody Pretargeting. 4.

Selection of Biotin Conjugates for in Vivo Application

Based on Their Dissociation Rate from Avidin and

Streptavidin

AUTHOR(S):

Wilbur, D. Scott; Chyan, Ming-Kuan; Pathare, Pradip M.; Hamlin, Donald K.; Frownfelter, Milah B.; Kegley,

Brian B.

CORPORATE SOURCE:

Department of Radiation Oncology, University of

Washington, Seattle, WA, 98195, USA

SOURCE:

Bioconjugate Chemistry (2000), 11(4), 569-583

CODEN: BCCHES; ISSN: 1043-1802

PUBLISHER:

American Chemical Society

DOCUMENT TYPE:

Journal

LANGUAGE: English

An investigation was conducted to det. the affect of structural variation of biotin conjugates on their dissocn. rates from Av and SAv. This information was sought to help identify optimal biotin derivs. for in vivo applications. Fifteen biotin derivs. were conjugated with a cyanocobalamin (CN-Cbl) deriv. for evaluation of their "relative" dissocn. rates by size exclusion HPLC anal. Two biotin-CN-Cbl conjugates, one contg. unaltered biotin and the other contg. iminobiotin, were prepd. as ref. compds. for comparison purposes. The first structural variations studied involved modification of the biotinamide bond with a N-Me moiety (i.e., sarcosine conjugate), lengthening the valeric acid side chain by a methylene unit (i.e., homobiotin), and replacing the biotinamide bond with thiourea bonds in two conjugates. The rate of dissocn. of the biotin-CN-Cbl deriv. from Av and SAv was significantly increased for biotin derivs. contg. those structural features. Nine addnl. biotin conjugates were obtained by coupling amino acids or functional group protected amino acids to the biotin moiety. In the conjugates, the biotin moiety and biotinamide bond were not altered, but substituents of various sizes were introduced .alpha. to the biotinamide bond. The results obtained from HPLC analyses indicated that the rate of dissocn. from Av or SAv was not affected by small substituents .alpha. to the biotinamide (e.g., Me, hydroxymethyl, and carboxylate groups), but was significantly increased when larger functional groups were present. On the basis of the results obtained, it appears that biotin conjugates which retain an unmodified biotin moiety and have a linker mol. conjugated to it that has a small functional group (e.g., hydroxymethylene or carboxylate) .alpha. to the biotinamide bond are excellent candidates for in vivo applications. These structural features are obtained in the biotin amino acid conjugates: biotin-serine, biotin-aspartate, biotin-lysine, and biotin-cysteine. Importantly, these biotin derivs. can be readily conjugated with other mols. for specific in vivo applications. In our studies, these derivs. will be used in the design of new biotin conjugates to carry radionuclides for cancer therapy using the pretargeting approach. THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 79 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 4 ibib abs

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:642438 CAPLUS

DOCUMENT NUMBER: 129:274233

TITLE: Biotin determination by three different methods.

Specificity and application to urine and plasma

ultrafiltrates of patients with and without disorders

in biotin metabolism

AUTHOR(S): Baur, Barbara; Suormala, Terttu; Bernoulli, Claudia;

Baumgartner, E. Regula

CORPORATE SOURCE: Metabolic Unit, Children's Hospital, Univ. Basel,

Basel, CH-4005, Switz.

SOURCE: International Journal for Vitamin and Nutrition

Research (1998), 68(5), 300-308 CODEN: IJVNAP; ISSN: 0300-9831

PUBLISHER: Hogrefe & Huber Publishers

DOCUMENT TYPE: Journal LANGUAGE: English

AB A microbiol., an avidin-binding, and a streptavidin-binding method for biotin detn. were compared. All 3 methods detected biotin equally well but they exhibit different specificities for derivs. of biotin. The microbiol. assay has the highest specificity and is the method of choice for biotin detn. in biotinidase-deficient patients. The specificity of streptavidin-binding was not investigated so far. Application of the 3 methods to urine samples of patients with and without biotin therapy indicated that only 50% of biotin equiv. measured with the avidin method

correspond to authentic biotin as previously shown. The other 50% comprise mainly bisnorbiotin and biotin-d-sulfoxide. HPLC-sepn. of urine samples prior to assay confirmed this finding and revealed a bisnorbiotin oxidn. product and an unknown compd. as further biotin metabolites. The latter was measurable by all 3 methods and not detectable in plasma ultrafiltrate. This was the only metabolite which was able to restore deficient 3-methylcrotonyl-CoA carboxylase activity in biotin-deficient fibroblasts. The combination of the 3 methods together with HPLC-sepn. proved to be a valuable anal. tool for the identification of the main biotin metabolites in biol. fluids.

=> d 5 ibib abs

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1990:436530 CAPLUS

DOCUMENT NUMBER: 113:36530

TITLE: Sodium-dependent biotin transport into brush-border

membrane vesicles from rat kidney

AUTHOR(S): Baur, Barbara; Wick, Hugo; Baumgartner, E. Regula

CORPORATE SOURCE: Metab. Unit, Univ. Child. Hosp., Basel, CH-4058,

Switz.

SOURCE: American Journal of Physiology (1990), 258(4, Pt. 2),

F840-F847

CODEN: AJPHAP; ISSN: 0002-9513

DOCUMENT TYPE: Journal LANGUAGE: English

The mechanisms of biotin reabsorption in rat kidney cortex were investigated using isolated brush-order membrane vesicles. An inwardly directed Na+ gradient specifically stimulated a transient biotin overshoot. Biotin transport was not affected by a valinomycin-induced K+-diffusion potential, and biotin--Na+ stoichiometry was found to be 1:1. As a function of concn., the uptake showed satn. in the presence of a Na+ gradient with an apparent Km of 55 .mu.M and Vmax of 217 pmol .times. mg protein-1 .times. 25 s-1. Desthiobiotin, 250 .mu.M, norbiotin, bisnorbiotin, thioctic acid, valeric acid, probenecid, and nonanoic acid inhibited the transport of 30 .mu.M biotin, whereas other biotin derivs., as well as biocytin and org. acids found in the urine of biotinidase-deficient patients, did not. Preloading of the vesicles with biotin, desthiobiotin, and norbiotin, and thioctic acid in the presence of Na+ increased initial uptake of biotin from the incubation medium (trans-stimulation). The results indicate that biotin absorption in rat kidney fulfills the criteria for a specific carrier-mediated and electroneutral Na+-biotin- cotransport in a 1:1 ratio. The results are discussed in context with congenital biotinidase deficiency in humans.

=> d 5 kwic

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

IT 57-66-9, Probenecid 109-52-4, Pentanoic acid, biological studies
112-05-0, Nonanoic acid 533-48-2, Desthiobiotin 669-72-7,
Norbiotin 1077-28-7, Thioctic acid 16968-98-2, Bisnorbiotin
RL: BIOL (Biological study)

(biotin and sodium cotransport by brush-border membrane of kidney cortex inhibition by)

=> d 6 ibib abs

L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1986:3747 CAPLUS

DOCUMENT NUMBER: 104:3747

TITLE: Biotin uptake by isolated rat liver hepatocytes

AUTHOR (S):

CORPORATE SOURCE:

SOURCE:

Bowers-Komro, Delores M.; McCormick, Donald B. Sch. Med., Emory Univ., Atlanta, GA, 30322, USA Annals of the New York Academy of Sciences (1985),

447 (Biotin), 350-8

CODEN: ANYAA9; ISSN: 0077-8923

DOCUMENT TYPE:

LANGUAGE:

Journal English

AB In a study using hepatocytes isolated from rat liver, biotin, an acid anion, appeared to be transported by a Na+-dependent process with an acid-anion carrier. The uptake process was followed by several metabolic functions, none of which appeared to predominate, as demonstrated by the absence of a definitive saturable process. The uptake process was temp. dependent, and general org. anions (bilirubin and cholic acid) were shown to be competitive.

=> d 6 kwic

L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

IT 58-85-5D, analogs 81-25-4 533-48-2 576-19-2 608-16-2 635-65-4, biological studies 1784-22-1 22342-46-7 53906-36-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(biotin transport by hepatocytes response to)

=> d 7 ibib abs kwic

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

1984:12447 CAPLUS

DOCUMENT NUMBER:

100:12447

TITLE:

Skin treatment compositions containing biotin

antagonists

INVENTOR(S):

Green, Martin Richard

PATENT ASSIGNEE(S):

Unilever PLC, UK

SOURCE:

Brit. UK Pat. Appl., 18 pp.

CODEN: BAXXDU

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PAT	ENT NO.	KIND	DATE	API	PLICATION NO.	DATE
GB :	 2114886	A1	19830901	GB	1983-4383	19830217
GB :	2114886	B2	19860604			•
US 4	4529587	Α	19850716	US	1983-462859	19830201
AU	8311432	A1 .	19830825	AU	1983-11432	19830215
AU .	548324	B2	19851205		,	
. EP	88542	A2	19830914	EP	1983-300809	19830217
EP	88542	A3	19850515			
EP	88542	B1	19880511			
	R: AT, B	E, CH, DE	, FR, IT,	LI, NL, S	SE	
JP :	58154508	A2	19830914	JP	1983-25484	19830217
JP (04045486	B4	19920727			
ZA	8301083	A	19840926	ZA	1983-1083	19830217
CA	1208135	A1	19860722	CA	1983-421827	19830217
AT :	34077	E	19880515	AT	1983-300809	19830217
PRIORITY	APPLN. IN	FO.:		GB 198	32-4958	19820219
				EP 198	33-300809	19830217

AB Skin prepns. or hair prepns. contg. 0.0001-0.5M biotin antagonists such as biotin sulfone [40720-05-6], homobiotin [1784-22-1], .alpha.-dehydrobiotin [10118-85-1], etc., and carriers are useful for the treatment of seborrhea. The antagonists block

the activity of the biotin-dependent enzyme acetyl-SCoA-carboxylase involved in sebum prodn. Thus, a topical lotion was prepd. contg. 0.005% biotin sulfone, 99.995 % EtOH and perfume q.s.

Skin prepns. or hair prepns. contg. 0.0001-0.5M biotin AB antagonists such as **biotin** sulfone [40720-05-6], homobiotin [1784-22-1], .alpha.-dehydrobiotin [10118-85-1], etc., and carriers are useful for the treatment of seborrhea. The antagonists block the activity of the biotin-dependent enzyme acetyl-SCoA-carboxylase involved in sebum prodn. Thus, a topical lotion was prepd. contg. 0.005% biotin sulfone, 99.995 % EtOH and perfume q.s.

=> d 8 ibib abs kwic

ANSWER 8 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

1983:50953 CAPLUS

DOCUMENT NUMBER:

98:50953

TITLE:

Biotin transport into fully differentiated 3T3-L1

cells

AUTHOR (S):

Cohen, Nadine D.; Thomas, Michal

CORPORATE SOURCE:

Dep. Biol. Chem., Wright State Univ., Dayton, OH,

45435, USA

SOURCE:

Biochemical and Biophysical Research Communications

(1982), 108(4), 1508-16

CODEN: BBRCA9; ISSN: 0006-291X

DOCUMENT TYPE:

Journal

English LANGUAGE:

The fully differentiated 3T3-L1 cell, like an adipocyte, contains high levels of the biotin-dependent enzymes pyruvate carboxylase and acetyl CoA carboxylase. Biotin transport into these cells demonstrates many of the characteristics of a carrier-mediated mechanism. The uptake process illustrates a nonlinear dependence on external biotin concn., marked temp. dependence, and considerable substrate specificity, as evidenced by studied with biotin analogs. Perhaps biotin transport into biotin-dependent mammalian cells occurs via a specific membrane carrier.

57-13-6, biological studies 58-85-5 107-92-6, biological studies TΤ 109-52-4, biological studies 110-01-0 120-93-4 142-62-1, biological 533-48-2 576-19-2 608-16-2 **669-72-7** 940-69-2 studies 1784-22-1 10118-85-1 30868-27-0 36846-64-7 53859-20-4 57828-26-9 53906-36-8

RL: BIOL (Biological study)

(transport of, by fibroblast, biotin transport in relation to)

=> d 9 ibib abs kwic

ANSWER 9 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

1974:56033 CAPLUS

DOCUMENT NUMBER:

80:56033

TITLE:

Relations between antivitamins and Trichomonas

vaqinalis

AUTHOR(S):

Khristov, Khr. P.

CORPORATE SOURCE:

Dermatol. Clin. Pleven, Pleven, Bulg.

SOURCE:

Scientia Pharmaceutica (1973), 41(3), 200-3

CODEN: SCPHA4; ISSN: 0036-8709

DOCUMENT TYPE:

Journal

LANGUAGE:

German

The biotin antagonist streptavidin [9013-20-1] inhibited growth AB of T. vaginalis in vitro at .geq.1.00 mg/ml, whereas homobiotin [1784-22-1] did not inhibit growth. 7-Dehydrocholesteryl bromide [50861-86-4], an antagonist of the growth inhibitor ergostanyl acetate, did not affect growth compared to controls.

The biotin antagonist streptavidin [9013-20-1] inhibited growth AB

of T. vaqinalis in vitro at .geq.1.00 mg/ml, whereas homobiotin [1784-22-1] did not inhibit growth. 7-Dehydrocholesteryl bromide [50861-86-4], an antagonist of the growth inhibitor ergostanyl acetate, did not affect growth compared to controls.

=> d 10 ibib abs kwic

ANSWER 10 OF 11 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 1971:66232 BIOSIS

DOCUMENT NUMBER:

BR07:66232

ISOLATION AND CHARACTERIZATION OF NOR BIOTIN AND TRIS NOR TITLE:

BIOTIN FROM CATABOLISM OF HOMO BIOTIN BY PSEUDOMONAS-SP.

AUTHOR(S):

RUIS H; BRADY R N; MCCORMICK D B; WRIGHT L D

SOURCE:

MCORMICK, DONALD B. AND LEMUEL D. WRIGHT (EDITED BY).

METHODS IN ENZYMOLOGY, VOL. XVIII. VITAMINS AND COENZYMES, PART A. XXI+688P. ILLUS. ACADEMIC PRESS: NEW YORK, N.Y.,

U.S.A, (1970) 409-413.

FILE SEGMENT:

BR; OLD

LANGUAGE:

Unavailable

669-72-7 (NOR BIOTIN)

1784-22-1 (HOMO BIOTIN) 16198-62-2 (TRIS NOR BIOTIN)

=> d 11 ibib abs kwic

ANSWER 11 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

1970:19318 CAPLUS

DOCUMENT NUMBER:

72:19318

TITLE:

Characterization of the biotin transport system in

Saccharomyces cerevisiae

AUTHOR (S):

Rogers, Thomas O.; Lichstein, Herman C.

CORPORATE SOURCE:

Coll. of Med., Univ. of Cincinnati, Cincinnati, OH,

SOURCE:

Journal of Bacteriology (1969), 100(2), 557-64

CODEN: JOBAAY; ISSN: 0021-9193

DOCUMENT TYPE: LANGUAGE:

Journal English

The characteristics of the biotin transport mechanism of S. cerevisiae were investigated in nonproliferating cells. Microbiol. and radioisotope assays were employed to measure biotin uptake. The vitamin existed intracellularly in both free and bound forms. Free biotin was extd. by boiling water. Chromatog. of the free ext. showed it to consist entirely of d-biotin. Cellular bound biotin was released by treating cells with 6N H2SO4. The rate of biotin uptake was linear with time for 10 min, reaching a max. at about 20 min followed by a gradual loss of accumulated free vitamin from the cells. Biotin was not degraded or converted to vitamers during uptake. Transport was temp.- and pH-dependent, optimum conditions for uptake being 30.degree. and pH 4.0. Glucose markedly stimulated biotin transport. In its presence, large intracellular free-biotin concn. gradients were established. Iodoacetate inhibited the glucose stimulation of biotin uptake. The rate of vitamin transport increased in a linear fashion with increasing cell mass. The transport system was satd. with increasing concns. of the vitamin. The apparent Km for uptake was 3.23 .times. 10-7M. Uptake of radioactive biotin was inhibited by unlabeled biotin and a no. of analogs including homobiotin, desthiobiotin, oxybiotin, norbiotin, and biotin sulfone. Proline, hydroxyproline, and 7,8-diaminopelargonic acid did not inhibit uptake. Unlabeled biotin and desthiobiotin exchanged with accumulated intracellular 14C-labeled biotin, whereas hydroxyproline did not.

IT 636-20-4 669-72-7 1784-22-1 2921-15-5 10406-89-0

RL: BIOL (Biological study)

(biotin absorption by Saccharomyces cerevisiae inhibition by)